1. Mengxin Qi, Xianglan Yi, Baohui Yue, Mingxiang Huang, Sheng Zhou, Jing Xiong. S100A6 inhibits MDM2 to suppress breast cancer growth and enhance sensitivity to chemotherapy. Breast Cancer Res. 2023;25(1):55. 2. Xianglan Yi , Mengxin Qi , Mingxiang Huang , Sheng Zhou, Jing Xiong. Honokiol Inhibits HIF-1α-Mediated Glycolysis to Halt Breast Cancer Growth. Front Pharmacol. 2022 Mar 8;13:796763. 3. Xianglan Yi , Liping Lou , Jun Wang , Jing Xiong , Sheng Zhou⁎. Honokiol antagonizes doxorubicin resistance in human breast cancer via miR-188-5p/FBXW7/c-Myc pathway. Cancer Chemother Pharmacol. 2021;87(5):647-656. 4. Xing M, Wang J, Yang Q, Wang Y, Li J, Xiong J⁎, Zhou S. FKBP12 is a predictive biomarker for efficacy of anthracycline-based chemotherapy in breast cancer. Cancer Chemother Pharmacol. 2019;84(4):861-872. 5. Xiong J, Li J, Yang Q, Wang J, Su T, Zhou S. Gossypol has anti-cancer effects by dual targeting MDM2 and VEGF in human breast cancer. Breast Cancer Res. 2017;19(1):27. 6. Liu T, Xiong J, Yi S, Zhang H, Zhou S, Gu L, Zhou M. FKBP12 enhances sensitivity to chemotherapy-induced cancer cell apoptosis by inhibiting MDM2. Oncogene. 2017;23;36(12):1678-1686. 7. Gu L, Zhang H, Liu T, Zhou S, Du Y, Xiong J, Yi S, Qu CK, Fu H, Zhou M. Discovery of Dual Inhibitors of MDM2 and XIAP for Cancer Treatment. Cancer Cell. 2016;30(4):623-636.
|
